Search results
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
As part of our aim to nurture young scientists, we are very pleased to introduce one of our new PhD students as part of a co-funding agreement with the Macular Society.
The Dr Jessie Mole lecture was inaugurated on 10 December 2001, in recognition of Jessie's outstanding contribution to BRPS, then RP Fighting Blindness and now Retina UK.
Retina UK invites expressions of interest for their inaugural career development grant call, which will result in an award of up to £1million as a strategic and targeted investment to result in a transformative impact for therapy for inherited retinal dystrophy.
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
